Download MendeleyDiscovery of a Novel Series of Potent and Selective Alkynylthiazole-Derived PI3K gamma Inhibitors.
Bandarage, U.K., Aronov, A.M., Cao, J., Come, J.H., Cottrell, K.M., Davies, R.J., Giroux, S., Jacobs, M., Mahajan, S., Messersmith, D., Moody, C.S., Swett, R., Xu, J.(2021) ACS Med Chem Lett 12: 129-135
- PubMed: 33488974
- DOI: https://doi.org/10.1021/acsmedchemlett.0c00573
- Primary Citation of Related Structures:
7KKE - PubMed Abstract:
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that control a wide variety of cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking. PI3Kγ plays a critical role in mediating leukocyte chemotaxis as well as mast cell degranulation, making it a potentially interesting target for autoimmune and inflammatory diseases. We previously disclosed a novel series of PI3Kγ inhibitors derived from a benzothiazole core. The truncation of the benzothiazole core led to the discovery of a structurally diverse alkynyl thiazole series which displayed high PI3Kγ potency and subtype selectivity. Further medicinal chemistry optimization of the alkynyl thiazole series led to identification of compounds such as 14 and 32 , highly potent, subtype selective, and CNS penetrant PI3Kγ inhibitors. Compound 14 showed robust inhibition of PI3Kγ mediated neutrophil migration in vivo .
Organizational Affiliation:
Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210, United States.
